You are here: Home » Companies
;
Business Standard

All you need to know about Glenmark's Favipiravir, the potential Covid drug

The drug will be available in the Indian market under the brand name FabiFlu at Rs 103 per tablet

Topics
Coronavirus

BS Author 

This is article Banner

The company

The company


Glenmark Pharmaceuticals became the first Indian company to secure drug regulator’s nod on manufacturing and marketing the antiviral drug, Favipiravir in India. It will now be available in the Indian market under the brand name FabiFlu at Rs 103 per tablet. The company said it would first cater to the domestic market requirements, however added that exports would depend on the regulatory requirements of other countries. Before this, Glenmark's net debt was over Rs 3,600 crore at the end of the March quarter. FabiFlu may give a decent push to its domestic business.

About drug

About drug
The Japanese flu drug, Favipiravir is made by a subsidiary of Fujifilm helping to treat patients with mild to moderate Covid-19 infection. However, a Japanese health official told the Mainichi Shimbun newspaper that the drug isn’t very effective in severe Covid-19 cases. The potential is significant -- the drug is to be used in Turkey, it is already available in Bangladesh, approval granted in the UAE, while the protocol is approved in Jordan. More than 15 companies are under the registration approval process to launch the drug in Egypt. Indonesia and Thailand have approved clinical protocol, several CIS countries like Ukraine have adopted it in Covid-19 protocol, and Iraq and Saudi Arabia are evaluating the drug.

Trials

Trials
The drug has shown promise in multiple global studies, with reduction in viral load, faster fever resolution, and faster clinical recovery. A Chinese trial in 340 people showed that the virus tended to be cleared in four days in those who received the drug, versus 11 days in those who went without. Glenmark has also been working to conduct phase 3 clinical trial on mild to moderate Covid-19 patients.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, June 22 2020. 14:03 IST
RECOMMENDED FOR YOU